Rights issue in Infant Bacterial Therapeutics AB (SE) — SEK 100 million

Carnegie acts as sole global co-ordinator and sole bookrunner in SEK 100m rights issue in IBT. IBT is a pharmaceutical company with a product in clinical Phase III with a vision to develop drugs influencing the infant microbiome, and thereby prevent or treat rare diseases affecting infants. IBT is currently developing the drug candidate IBP-9414. The ambition for IBP-9414 is to become the world’s first approved probiotical drug with the goal to prevent life threatening diseases in premature infants including NEC and sepsis.